reports
- Thomas Vranken
Onward Medical FIRST LOOK: Grant to assess ARC-BCI in stroke patients
Onward announces a new grant from the EIC for € 6m over 5-years (of which Onward receives almost € 2m) to assess ARC-BCI in stroke patients. The grant underlines the platform potential of Onward's technologies. We continue to look out to FDA approval for Onward's first product ARC-EX, expected by YE24. We reiterate our € 9.1 TP and Buy rating.
- Guy Sips
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Vranken
ONWARD Medical Awarded Grant to Study Potential for ARC-BCI Therapy to...
ONWARD Medical Awarded Grant to Study Potential for ARC-BCI Therapy to Restore Movement after Stroke Grant supports the first clinical trials studying the potential for brain-computer interface (BCI) and artificial intelligence (AI) technology to restore thought-driven movement after stroke Funding also supports technology development of ARC-BCI System and ARC-IM Lead Approximately 15 million people worldwide experience a stroke each year EINDHOVEN, the Netherlands, Nov. 19, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company ...
ONWARD Medical Schedules Webcast to Provide Q3 2024 Update and Year-to...
ONWARD Medical Schedules Webcast to Provide Q3 2024 Update and Year-to-Date Highlights Company to provide update on significant milestones and near-term plans, including its recent successful financing and agreements with Ottobock and CEA EINDHOVEN, the Netherlands, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will host a webcast to discuss its Q3 2024 business high...
ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024
ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024 EINDHOVEN, the Netherlands, Oct. 31, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its investigational ARC-EX System has been named one of TIME's Best Inventions of 2024. "We are grateful for TIME’s recognition of the ARC-EX System, which has the potential to impact hundreds of thousands of people with spinal cord injury and impaired hand and ...
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Jacob Mekhael
- Thomas Vranken
Onward Medical € 50m equity raise from Ottobock and institutional inve...
Last week, Onward announced an upsized € 50m capital increase, which included a € 22.5m ticket from Ottobock, a global player in the fields of prosthetics, orthotics and exoskeleton technology, as new cornerstone investor. The new shares were issued at € 5.00 p.s., representing a 12.6% discount vs. last closing price before deal announcement. We resume our coverage with a € 9.1 TP and Buy rating (from Suspended).
ONWARD® Medical Publishes Closing of Bookbuild Offering
ONWARD® Medical Publishes Closing of Bookbuild Offering THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Oct. 28, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today the closing of its previously announced private placement with institutional ...
ONWARD® Medical Publishes Prospectus for Listing of New Shares
ONWARD® Medical Publishes Prospectus for Listing of New Shares THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today that it has published a prospectus for the admission to listing of 10...
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Thomas Vranken
Onward Medical € 50m equity raise from Ottobock and institutional inve...
Onward has completed an upsized € 50m capital increase, which included a € 22.5m ticket from Ottobock, a global player in the fields of prosthetics, orthotics and exoskeleton technology, as new cornerstone investor. The new shares were issued at € 5.00 p.s., representing a 12.6% discount vs. last closing price. Given KBCS' involvement in the transaction, we temporarily suspended coverage until settlement on October 28.
ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capit...
ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital Increase with Cornerstone Investment from Ottobock SE & Co. KGaA THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Ottobock, a global leader in the fields of prosthetics, orthotics and exoskeleton technology, acquires c.10% of ONWARD Medical N.V.’s share capital and initiates strategic relationship Cash runway extended to two years or more Capital increase was upsized to EUR 50M on the basis of strong demand from high-quality long-o...
ONWARD® Medical lève avec succès 50 millions d’euros dans le cadre d’u...
ONWARD® Medical lève avec succès 50 millions d’euros dans le cadre d’une levée de fonds majorée avec le soutien d’Ottobock SE & Co. KGaA Ottobock, un leader mondial dans le domaine des prothèses, des orthèses et des exosquelettes, acquiert environ 10% du capital d’ONWARD Medical N.V. concrétisant un partenariat stratégique La couverture des besoins en trésorerie est étendue à deux ans ou plus Le montant de la levée de fonds a été majoré à 50 millions d’euros en raison de la forte demande d’investisseurs « long-only » de qualité et d’investisseurs spécialisés dans le secteur ...
- Kristof Samoy
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Onward Medical Launches capital increase for indicative amount of € c....
Onward launches a capital increase for an indicative amount of € c.40m, including a € 22.5m cornerstone investment from Ottobock, a global player in the fields of prosthetics, orthotics and exoskeleton technology. Euronext halts trading during the bookbuilding period to allow broader investor participation. Due to the transaction, we temporarily suspend coverage.
ONWARD® Medical lance une augmentation de capital d’un montant d’envir...
ONWARD® Medical lance une augmentation de capital d’un montant d’environ 40 millions d’euros dont 22,5 millions d’engagement ferme de la part d’Ottobock SE & Co. KGaA NE PAS DISTRIBUER OU DIFFUSER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS, AU CANADA, EN AUSTRALIE OU AU JAPON OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE LA DISTRIBUTION OU LA DIFFUSION SERAIT ILLÉGALE. D'AUTRES RESTRICTIONS SONT APPLICABLES. VEUILLEZ CONSULTER L'AVIS IMPORTANT À LA FIN DU COMMUNIQUÉ DE PRESSE. CE COMMUNIQUÉ DE PRESSE CONTIENT DES INFORMATIONS PRIVÉES AU SENS DE L'ARTICLE (7)(1) DU RÈGLEMENT EUROPÉEN S...
ONWARD® Medical Launches Capital Increase for Indicative Amount of c. ...
ONWARD® Medical Launches Capital Increase for Indicative Amount of c. EUR 40 Million including EUR 22.5 Million Cornerstone Investment from Ottobock SE & Co. KGaA NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) O...
- Hilde Van Boxstael
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Wim Lewi
ONWARD® Medical Announces Changes to Board of Directors, Including Add...
ONWARD® Medical Announces Changes to Board of Directors, Including Addition of Medtech Leader Rob ten Hoedt as Incoming Chairman Ten Hoedt is a former Medtronic President and Executive Committee Member; also a former Chairman of MedTech Europe Commercial and digital health expert Rahma Samow will also join as Director Current Board Chairman Jan Ohrstrom and Director Fred Colen to retire from the Board at year-end after 8 years of service EINDHOVEN, the Netherlands, Oct. 21, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative...
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.